Biotech Archives - Page 123 of 795

2 minute read

Nevro Announces Coverage Update From Carelon Healthcare For The Treatment Of Painful Diabetic Neuropathy

January 18, 5:19 PM

Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Carelon Healthcare, a healthcare services

NVRO

4 minute read

Coherus Presents Phase 2 Clinical Data On Casdozokitug, A First-in-Class IL-27-Targeted Antibody, At The 2024 ASCO GI Cancers Symposium; The Primary Endpoint Of The Lead-in Portion Of The Study Was Safety And Tolerability

By Benzinga Newsdesk

January 18, 5:16 PM

– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses –– Data support casdozo as a promising novel immuno-oncology agent with

CHRS

3 minute read

Verastem Oncology Granted Fast Track Designation For Combination Of Avutometinib And Sotorasib For The Treatment Of KRAS G12C-Mutant Non-Small Cell Lung Cancer

By Benzinga Newsdesk

January 18, 5:00 PM

Ongoing RAMP 203 Trial Assessing a More Complete Vertical Blockade with RAF/MEK and KRAS G12C Inhibition Along RAS Pathway to Improve Outcomes in KRAS G12C-Mutant NSCLCConfirmed Responses Observed in Both KRAS G12C

VSTM

2 minute read

SOPHiA GENETICS Enhances RareCyte Precision Biology Services Portfolio With SOPHiA DDM

By Benzinga Newsdesk

January 18, 4:03 PM

RareCyte will use the SOPHiA DDM™ Platform to support its oncology testing panelBOSTON and ROLLE, Switzerland, Jan. 18, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and a

SOPH

1 minute read

Halozyme’s Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion

By Vandana Singh

January 18, 2:28 PM

Explore Halozyme Therapeutics' promising financial outlook up to 2028. Discover revenue forecasts, earnings projections, and market insights.

ARGX

2 minute read

Why Is Cancer Focused Novocure Stock Trading Higher Today?

By Vandana Singh

January 18, 1:19 PM

Novocure's TTFields therapy gains FDA acceptance for non-small cell lung cancer treatment after platinum-based therapy. PMA filing under FDA review. Decision expected in 2H 2024.

NVCR

3 minute read

Optinose Announces The Publication Of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE In The Journal Of Allergy And Clinical Immunology: In Practice

By Benzinga Newsdesk

January 18, 1:02 PM

XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized controlled Phase 3 Clinical Trials (ReOpen1 and ReOpen2) FDA

OPTN

4 minute read

Deciphera Pharmaceuticals Results Of INTRIGUE Study Long-Term Follow-Up, In The Primary Analysis Of The AP-ITT Population Based On A Data Cut Of September 1, 2021, The Primary Endpoint Was Not achieved

By Benzinga Newsdesk

January 18, 12:17 PM

Results of INTRIGUE Study Long-Term Follow-UpIn INTRIGUE, 453 patients in the all-patient intent-to-treat population (AP-ITT) with second-line GIST were randomized 1:1 to receive QINLOCK 150 mg once daily (n=226) or

DCPH

5 minute read

Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results From INTRIGUE Phase 3 Clinical Study In Second-Line GIST Patients At The 2024 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

By Benzinga Newsdesk

January 18, 12:14 PM

– Median Overall Survival for QINLOCK® of 35.5 Months Versus 31.5 Months for Sunitinib in the All-Patient Intent-to Treat-Population –– Long-Term Safety Profile Consistent with Primary Analysis Showing Fewer

DCPH

2 minute read

Allied Digestive Health, A Wholly-owned Operating Company Of Fortive Corp, And Provation Sign Agreement For Enhanced Patient Care

By Benzinga Newsdesk

January 18, 10:03 AM

Esteemed gastroenterology management company cites cloud-based technology as top reason to move facilities to Provation ApexAllied Digestive Health (ADH), the beacon of cutting-edge gastroenterology (GI) services across

FTV